title: Atrial natriuretic peptide and renal dopaminergic system: a positive friendly relationship?
abstract: Sodium metabolism by the kidney is accomplished by an intricate interaction between signals from extrarenal and intrarenal sources and between antinatriuretic and natriuretic factors. Renal dopamine plays a central role in this interactive network. The natriuretic hormones, such as the atrial natriuretic peptide, mediate some of their effects by affecting the renal dopaminergic system. Renal dopaminergic tonus can be modulated at different steps of dopamine metabolism (synthesis, uptake, release, catabolism, and receptor sensitization) which can be regulated by the atrial natriuretic peptide. At tubular level, dopamine and atrial natriuretic peptide act together in a concerted manner to promote sodium excretion, especially through the overinhibition of Na+, K+-ATPase activity. In this way, different pathological scenarios where renal sodium excretion is dysregulated, as in nephrotic syndrome or hypertension, are associated with impaired action of renal dopamine and/or atrial natriuretic peptide, or as a result of impaired interaction between these two natriuretic systems. The aim of this review is to update and comment on the most recent evidences demonstrating how the renal dopaminergic system interacts with atrial natriuretic peptide to control renal physiology and blood pressure through different regulatory pathways.
authors.affiliation: Department of Pathophysiology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, CONICET, INFIBIOC, 1113 Buenos Aires, Argentina.
authors.forename: Marcelo Roberto
authors.initials: MR
authors.lastname: Choi
authors.affiliation: Department of Pathophysiology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, CONICET, INFIBIOC, 1113 Buenos Aires, Argentina.
authors.forename: Natalia Lucía
authors.initials: NL
authors.lastname: Rukavina Mikusic
authors.affiliation: Department of Pathophysiology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, CONICET, INFIBIOC, 1113 Buenos Aires, Argentina.
authors.forename: Nicolás Martín
authors.initials: NM
authors.lastname: Kouyoumdzian
authors.affiliation: Department of Pathophysiology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, CONICET, INFIBIOC, 1113 Buenos Aires, Argentina.
authors.forename: María Cecilia
authors.initials: MC
authors.lastname: Kravetz
authors.affiliation: Department of Pathophysiology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, CONICET, INFIBIOC, 1113 Buenos Aires, Argentina.
authors.forename: Belisario Enrique
authors.initials: BE
authors.lastname: Fernández
mesh_terms: D009320:Atrial Natriuretic Factor / Q000378:metabolism*; D001794:Blood Pressure / Q000502:physiology; D006152:Cyclic GMP / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000378:metabolism / Q000473:pathology; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D012964:Sodium / Q000378:metabolism*; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
chemical_list: D009320:Atrial Natriuretic Factor; D012964:Sodium; D000254:Sodium-Potassium-Exchanging ATPase; D006152:Cyclic GMP; D004298:Dopamine